Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)

NCT04917042 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT04917042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04917042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 25, 2021
Completion date
December 31, 2026
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral nerve sheath tumor